{
  "id": 11141079,
  "title": "Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes",
  "url": "https://urgent.news/2026/10/01/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T07:32:21.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes"
  },
  "original_language": "en",
  "account": null,
  "summary": "In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1 Detailed results from the Phase III trial […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes",
        "url": "https://urgent.news/2026/10/01/new-investigational-drug-delivers-up-to-23-3-weight-loss-in-people",
        "published": "2026-10-01T00:40:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}